Premium
Plasmin‐α2‐plasmin inhibitor complex in plasma of patients with disseminated intravascular coagulation
Author(s) -
Takahashi Hoyu,
Hanano Masaharu,
Takizawa ShinIchiro,
Tatewaki Wataru,
Shibata Akira
Publication year - 1988
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830280306
Subject(s) - plasmin , liter , disseminated intravascular coagulation , hyperfibrinolysis , fibrinolysis , coagulation , chemistry , acute promyelocytic leukemia , medicine , biochemistry , enzyme , retinoic acid , gene
Plasmin‐α2‐plasmin inhibitor (α2PI) complex, an indicator of in vivo plasmin generation, was measured in the plasma of 48 patients with disseminated intravascular coagulation (DIC), by enzyme‐linked immunosorbent assay (ELISA). Plasmin‐α2PI complex was markedly elevated to 7.9 ± 4.26 mg/liter (mean ± SD) in DIC at presentation, with normal values at less than 0.8 mg/liter. The concentration of plasmin‐α2PI complex changed in parallel with the course of DIC and decreased to 1.9 ± 1.49 mg/liter (n = 28) in remission. Among various underlying disorders, DIC, in patients with acute promyelocytic leukemia, had the highest complex levels (mean 10.8 mg/liter), and septic patients had the lowest levels (mean 3.4 mg/liter). No significant correlation was found between FDP and plasmin‐α2PI complex. These results indicate that the quantitative assay of plasmin‐α2PI complex in plasma would be valuable in the assessment of hyperfibrinolysis in DIC.